TCG Advisory Services LLC Boosts Holdings in Bristol-Myers Squibb (NYSE:BMY)

TCG Advisory Services LLC grew its position in shares of Bristol-Myers Squibb (NYSE:BMY) by 99.1% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 11,258 shares of the biopharmaceutical company’s stock after purchasing an additional 5,604 shares during the period. TCG Advisory Services LLC’s holdings in Bristol-Myers Squibb were worth $578,000 at the end of the most recent quarter.

Several other institutional investors have also recently made changes to their positions in BMY. Concord Wealth Partners raised its stake in Bristol-Myers Squibb by 6.6% in the third quarter. Concord Wealth Partners now owns 21,619 shares of the biopharmaceutical company’s stock valued at $1,255,000 after purchasing an additional 1,330 shares in the last quarter. Lindbrook Capital LLC raised its position in shares of Bristol-Myers Squibb by 2.3% during the 3rd quarter. Lindbrook Capital LLC now owns 8,060 shares of the biopharmaceutical company’s stock valued at $468,000 after buying an additional 182 shares in the last quarter. ETF Store Inc. bought a new stake in shares of Bristol-Myers Squibb during the 3rd quarter worth $215,000. Taylor Frigon Capital Management LLC grew its position in Bristol-Myers Squibb by 2.8% in the third quarter. Taylor Frigon Capital Management LLC now owns 19,968 shares of the biopharmaceutical company’s stock worth $1,159,000 after acquiring an additional 535 shares in the last quarter. Finally, BluePath Capital Management LLC purchased a new stake in Bristol-Myers Squibb during the third quarter valued at about $52,000. Institutional investors own 76.41% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts have recently commented on the company. Societe Generale lowered Bristol-Myers Squibb from a “buy” rating to a “hold” rating in a research report on Monday, March 11th. Wells Fargo & Company increased their price target on shares of Bristol-Myers Squibb from $51.00 to $52.00 and gave the company an “equal weight” rating in a research report on Thursday, April 18th. Redburn Atlantic cut shares of Bristol-Myers Squibb from a “buy” rating to a “neutral” rating and cut their price objective for the company from $77.00 to $54.00 in a research note on Tuesday, February 6th. William Blair reiterated a “market perform” rating on shares of Bristol-Myers Squibb in a research report on Monday, April 1st. Finally, Barclays cut their price target on shares of Bristol-Myers Squibb from $51.00 to $43.00 and set an “equal weight” rating for the company in a research report on Friday, April 26th. One investment analyst has rated the stock with a sell rating, fifteen have issued a hold rating and four have given a buy rating to the company’s stock. Based on data from MarketBeat, Bristol-Myers Squibb presently has an average rating of “Hold” and a consensus target price of $60.00.

Bristol-Myers Squibb Trading Up 0.7 %

NYSE BMY traded up $0.29 during trading on Friday, hitting $43.99. The company had a trading volume of 12,104,489 shares, compared to its average volume of 14,314,010. The company’s fifty day moving average is $50.37 and its 200-day moving average is $50.65. The company has a market cap of $89.17 billion, a price-to-earnings ratio of -14.19, a price-to-earnings-growth ratio of 14.82 and a beta of 0.45. The company has a current ratio of 1.11, a quick ratio of 0.99 and a debt-to-equity ratio of 2.99. Bristol-Myers Squibb has a one year low of $43.33 and a one year high of $69.10.

Bristol-Myers Squibb (NYSE:BMY) last released its quarterly earnings results on Thursday, April 25th. The biopharmaceutical company reported ($4.40) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($4.53) by $0.13. Bristol-Myers Squibb had a negative net margin of 13.50% and a positive return on equity of 8.83%. The company had revenue of $11.87 billion during the quarter, compared to the consensus estimate of $11.45 billion. During the same period in the prior year, the firm earned $2.05 earnings per share. Bristol-Myers Squibb’s revenue was up 4.7% on a year-over-year basis. On average, sell-side analysts predict that Bristol-Myers Squibb will post 0.59 earnings per share for the current year.

Bristol-Myers Squibb Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Wednesday, May 1st. Shareholders of record on Friday, April 5th were issued a $0.60 dividend. The ex-dividend date of this dividend was Thursday, April 4th. This represents a $2.40 dividend on an annualized basis and a yield of 5.46%. Bristol-Myers Squibb’s dividend payout ratio (DPR) is -77.42%.

Bristol-Myers Squibb Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.